Librede Inc. Receives Patent for Cannabidiolic Acid (CBDA) Production in Yeast
July 24, 2018 05:00 AM Eastern Daylight Time
CARLSBAD, Calif.–Librede, a leader in natural cannabinoid biosynthesis, has been granted a new patent for the production of cannabidiolic acid (CBDA) in microorganisms. The patent, Production of Cannabidiolic Acid in Yeast, describes the modification of yeast to produce CBDA from simple feedstocks such as sugar. CBDA is a naturally occurring cannabinoid found in hemp and cannabis which is used to produce cannabidiol (CBD). Cannabidiol has been shown to have a wide range of therapeutic properties, including treatment of epilepsy, for which a CBD-based therapeutic has won recent FDA approval. Librede’s fermentation-based cannabinoid production platform has demonstrated that natural CBD can be produced outside of the cannabis plant using yeast, in a process that is similar to making beer. Librede is now in the process of continuing technology development through optimization and scaling for industrial production in large fermenters. Dr. Anthony Farina, Librede’s Chief Scientific Officer, explains: “We have been building our platform around the natural biochemistry in the cannabis plant that gives rise to a diverse set of compounds, with our focus being on therapeutic applications. Having engineered cannabidiol synthesis in the laboratory, we are now beginning the process of scaled up production.”
Fermentation for the production of high value, complex, natural products offers a preferred route to synthesis at an industrial scale. Librede’s biosynthetic approach has several potential advantages over agricultural-based methods including protection from supply volatility, improved consistency, reduced cost, and lower environmental impact. Dr. Jason Poulos, CEO of Librede, explains: “The use of fermentation to produce these compounds represents the future of industrial scale cannabinoid production. As more cannabinoids are shown to have therapeutic value, we must find a way to produce these compounds in a sustainable way. Utilizing the synthetic power of biology allows us economical access to these compounds while minimizing environmental impacts. The future of all cannabinoid production may not be large farm fields but instead compact and highly efficient fermenters.”
Librede is a synthetic biology company that uses biologically-based approaches to produce high value natural products with a focus on cannabinoids. Librede’s patented yeast-based cannabinoid production platform can provide therapeutic cannabinoids to diverse markets in an economically and environmentally sustainable way.
ProtaBank is a repository for storing, querying, analyzing, and sharing protein design and engineering data in an actively maintained and updated database.
Founded in 2016, Lucendi, Inc. is a leading innovator and developer of AI-enabled smart measurement platforms for cost-effective and high-performance micro-object detection and characterization. Lucendi technology portfolio and IP are based on computational microscopy and holographic imaging coupled with innovative image processing, big data and machine learning approaches. Lucendi’s core technologies are cost-effective, robust and field-portable, which make them adaptable to a wide variety of applications.
A team of researchers from Baltimore-based Johns Hopkins Medicine developed an electronic triage tool to risk-stratify patients in its emergency departments.
The team — led by Scott Levin, PhD, associate professor of emergency medicine at the Johns Hopkins University School of Medicine — built the clinical decision support tool using machine learning algorithms to predict the likelihood of adverse patient outcomes.